Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ABBV-CLS-579 + unspecified PD-1 antibody |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ABBV-CLS-579 | ABBV-CLS579|ABBV-CLS 579 | Limited information is currently available on ABBV-CLS-579, a putative PTPN2 inhibitor (Mar 2022). | ||
unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04417465 | Phase I | ABBV-CLS-579 ABBV-CLS-579 + unspecified PD-1 antibody | First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors | Recruiting | USA | 4 |